(Reuters) -Contract research organizations are reporting better-than-expected second-quarter profit, a sign that Wall Street analysts say reflects a rebound in biotech and pharmaceutical spending ...

Nov 6 (Reuters) - Charles River Laboratories (CRL.N), opens new tab raised its full-year profit forecast after beating analysts' estimates for quarterly results as the contract research firm expects ...

After a blustery few years, the winds are shifting for biotech stocks. A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting ...